Dr. Tri M. Le, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Virginia School of Medicine (2010)
- Years since graduation
- 16
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 230
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Medical school: University of Virginia School of Medicine
- 2010Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
VA license 0101260583
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Virginia Medical Center Charlottesville, VA
Medical groups
- University of Virginia Physicians Group (1,717 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 230
- Services billed
- 1,186
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 249 | 87 |
| Established patient office or other outpatient visit, 30-39 minutes | 245 | 123 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 88 | 30 |
| New patient office or other outpatient visit, 60-74 minutes | 55 | 54 |
| Hospital discharge day management, 30 minutes or less | 26 | 25 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 22 | 22 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ondansetron Hcl Other prescribers in Charlottesville, VA | 53 |
| Prochlorperazine Maleate Other prescribers in Charlottesville, VA | 44 |
| Eliquis (apixaban) Other prescribers in Charlottesville, VA | 38 |
| Dexamethasone Other prescribers in Charlottesville, VA | 26 |
| Olanzapine Other prescribers in Charlottesville, VA | 25 |
| Creon (lipase/protease/amylase) Other prescribers in Charlottesville, VA | 17 |
| Duloxetine Hcl Other prescribers in Charlottesville, VA | 16 |
| Famotidine Other prescribers in Charlottesville, VA | 16 |
| Everolimus | 15 |
| Ondansetron Odt (ondansetron) Other prescribers in Charlottesville, VA | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 4 payments worth $243 in total to this clinician.
| Pfizer Inc. | $102 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $102 |
| Daiichi Sankyo Inc. | $24.03 |
| AbbVie Inc. | $15.09 |
| Food and Beverage | $243 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $122,489 in research payments for these studies, mostly to the institutions running them.
- A phase 3 multi center,open label,sponsor blinded,randomized study of azd0901 monotherapy compared with investigator s choice of therapy in second or later line adult participants with advanced metastatic gastric or g…
AstraZeneca Pharmaceuticals LP - Phase II single arm study of durvalumab and bevacizumab following transarterial radioembolization using yttrium 90 glass microspheres therasphere in unresectable hepatocellular carcinoma amenable to locoregional therapy
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.